- Generic Victoza is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market.
- This launch adds to Teva's continued commitment to its complex generic medicine portfolio.
- Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
Teva Pharmaceutical Industries Launches Authorized Generic Of Victoza In United States
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.